HIPRA is a diverse and innovative pharmaceutical company that strives to be the Reference in Prevention for Animal Health. Also read more about the HIPRA UNIVERSITY at the bottom of this post.

HIPRA is devoted to the development and manufacturing of a complete product range addressing prevention and the reduction of diseases within the production animal sectors (poultry, swine, bovine and aqua). The company is known for its efforts in the development of innovative vaccines and its continued advances and contributions in the ever-growing science of animal vaccination and immunisation.

HIPRA’s range of products include pharmaceuticals which were developed with an improved ease of administration during the treatment of animals and vaccines with complementary diagnostic kits to provide farmers and veterinarians with a complete set of prevention tools to aid in the development and improvement of a holistic management strategy.

HIPRA is proud to supply products that have been approved and registered with the European Medicine Agency and continue to research methods to enhance the efficacy and safety of existing vaccines, while searching and developing innovative vaccines for diseases that continue to not have methods of prevention.

The company has been the first to develop such vaccines as STARTVAC®, with its innovative approach of preventing the development of the Biofilm associated with mastitis causing bacteria such coagulase-negative staphylococci (CNS) and Staph. aureus.

HIPRA is a growing company and supplies products to over 125 countries around the world. The company manages to do this through the efforts of their international team (over 1 400 employees) and its regional subsidiaries and dedicated distributors.

HIPRA Southern Africa (Pty) Ltd has a dedicated team to assist you with product information and technical support. The South African subsidiary’s office is located at Unit 5, Atterbury Estate, 19 Frikkie de Beer Street, Menlyn, Pretoria, and the telephone number is: 012 348 1506.

The bovine range:

 

 

HIPRABOVIS® 4 is a tetravalent combined vaccine against IBR, PI-3, BVD and BRSV. HIPRABOVIS® 4 protects your entire farm and is known for its versatility. A farm has several types of animals, or age groups: cows, heifers and calves, and each of these age groups has different problems and needs, which also occur at different times during their development and phase of production. In the face of all this, a single vaccine for the entire farm, adapted to each group’s needs, enables a comprehensive approach to protecting and managing the control of the bovine respiratory diseases on a farm.

Technical data sheet:

HIPRABOVIS® 4

Combined vaccine, IBR, PI-3, BVD and BRS viruses, in injectable suspension.

Composition per ml:

Inactivated infectious bovine rhinotracheitis virus (IBR), strain LA ≥ 10⁷ TCID₅ₒ; inactivated parainfluenza-3 virus (PI-3), strain SF4 ≥ 480 HAU; inactivated bovine diarrhea virus (BVD), strain NADL ≥ 10 TCID₅ₒ; live bovine respiratory syncytial virus (BRSV), strain Lym-56 ≥ 10⁴ TCID₅ₒ.

Indications:

Adult cattle: Prevention of infectious bovine rhinotracheitis (IBR), infectious pustular vulvo-vaginitis (IPV) and mucosal disease (BVD).

Calves: Prevention of infectious bovine rhinotracheitis (IBR), parainfluenza-3 (PI-3), mucosal disease or bovine viral diarrhoea (BVD) and pneumonia caused by bovine respiratory syncytial virus. It can be used at any stage of pregnancy and lactation.

Dosage and method of administration:

Dissolve the freeze-dried fraction with the liquid fraction of the vaccine and make sure it is completely resuspended before proceeding to administering the vaccine. The suspension can be administered intramuscularly or subcutaneously as a 3ml dose per animal.

Calves: Immunise with one dose 4 to 6 weeks of age. Re-immunise 21 to 30 days later, especially when very young calves are immunised. Administer a booster vaccination once a year.

Heifers: Immunise with one dose. Re-immunise 21 to 30 days later, one month before the first mating. Administer a booster vaccination once a year.

Cows: Immunise with one dose. Re-immunise 21 to 30 days later. Administer a booster vaccination once a year. Once the freeze-dried fraction has been resuspended, the vaccine must be administered within three hours. It is advisable to administer the vaccine when the liquid fraction is at a temperature of +15 and +25°C.  Shake before use.

Withdrawal period:

Milk: none; meat: 21 days.

Undesirable effects:

A sporadic anaphylactic reaction may appear in some sensitive animals. In such a case administer an antihistamine treatment.

The way that STARTVAC® works as a mastitis prevention tool, is that the active components in the polyvalent vaccine are strengthening the “animal” pillar of the udder health management system, and this complement and boost the efforts in and from the other pillars.

STARTVAC® works in two ways:

Firstly, regarding the environmental pathogens, the vaccine primes the cow’s immune system to better respond during an infection caused by Escherichia coli or coliform pathogens and reduces the negative effects seen: milk yield drops, blue udder/toxic mastitis, higher somatic cell counts (SCC). Thus STARTVAC® causes the mastitic animals to heal quicker, respond more efficiently and favourably to treatments and finally suffer fewer and less severe clinical cases.

Secondly, the vaccine protects the cows against the spread of contagious Staphylococcus aureus by preventing the building blocks of the biofilm being assembled to surround and protect the bacteria. By preventing development of this impenetrable layer, the vaccine aids the immune system and antibiotics in combating the infection, resulting in a reduced reproduction rate (lower numbers of bacteria in the environment and udder, meaning that the risk of new infections is also reduced).

Similarly, STARTVAC® plays a role in improving the chances of self-cure in clinical cases seen in early and young lactating animals, which is another step in reducing the pathogen load in the herd. The vaccine also decreases the elevated SCC levels in chronically infected cows.

STARTVAC®

Inactivated vaccine against bovine mastitis.

Composition per ml:

One dose (2ml) contains: E. coli J5 inactivated >50 RED60*, S. aureus CP8 inactivated strain SP140 expressing SAAC >50RED80; *(Slime Associated Antigen Complex (SAAC)); * RED: Rabbit effective dose in 60% or 80% of animals (serology); liquid paraffin: 18,2mg; benzyl alcohol: 20mg.

Indications:

For the immunisation of dairy cows in stables with recurring problems of mastitis, to reduce the incidence of sub-clinical mastitis and to reduce the incidence and severity of clinical signs of mastitis caused by Staphylococcus aureus, (CNS), Escherichia coli and coliforms.

The complete schedule of immunisation induces immunity from approximately 13 days after the first injection until around 78 days after the third injection (equivalent to 130 days after calving).

Dosage and method of administration:

Intramuscular use. It is preferable that the injections are administered on alternate sides of the neck.

Administer one dose (2ml) by deep intramuscular injection into the neck muscles according to the following indications:

  • First injection at 45 days before the expected date of parturition.
  • Second injection 35 days afterwards (10 days before the expected date of parturition).
  • Third injection 62 days after the second injection (corresponding to 52 days after parturition).

The complete immunisation programme should be repeated in each pregnancy.

Contraindications and adverse reactions:

No contraindications.

Temporary slight to moderate local reactions may occur after a dose of the vaccine is administered. They mainly include: swelling (up to 5cm2 on average), which vanish one or two weeks later at most. In some cases, pain may also appear at the immunisation site that spontaneously subsides by four days later at most.

There may be a transient increase in body temperature of about +1°C and up to +2°C in some cows in the first 24 hours after injection. Animals immunised with an overdose showed no adverse reactions other than those observed after administration of a single dose of the vaccine. If you notice any serious effects or any other not listed in this leaflet, please report it to your veterinarian.

Global testimonials:

No matter where in the world you are, STARTVAC® can play a role in the management and reduction of mastitis. These testimonials are from consulting veterinarians and/or farmers which have seen and experienced the benefits of STARTVAC® for themselves. To view the scientific papers, short posters, etc. please visit www.startvac.com.

Spain:

Immunisation with STARTVAC® on this farm is having a great impact contributing to minimise spreading of S. aureus within the herd, improving udder health and reducing BTSCC.” – Dr Oriol Franquesa, et al., consultant and milk quality specialist veterinarian, Q-LLET, Spain. Published at the 2016 World Buiatrics Congress.

Portugal:

The benefits obtained with the vaccination programme justify their use and maintenance on the farm and must be considered on mastitis control programmes.” – AR Pereira, SEGALAB, Porto, Portugal. Published at the 2016 World Buiatrics Congress.

Netherlands:

Cows suffer less severe clinical mastitis and cure rates have improved after vaccination.” – Dr A Veenkamp, DAP Flevoland, Zeewolde, Netherlands. Published at the 2016 World Buiatrics Congress.

Italy:

Vaccination can contribute to reduce the usage of antibiotic treatments, keeping under control also the issues related to antibiotic resistance.” – Dr A Angelucci, et al., Reparto Produzione Primaria, Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna, Italy. Published at the 2016 World Buiatrics Congress.

Denmark:

Translation: “STARTVAC® was started using the rolling protocol and after six months the selection of cull cows is no longer just for mastitis/high SCC animals, but now for other reasons as the average herd SCC is around 127 000 cells/ml. Before the introduction of STARTVAC® the farmer, Arne Østergaard from the farm SEGES, was treating a higher number of cows for mastitis than that of the national average and since using STARTVAC® he is treating fewer cows than the national average.” –  Arne Østergaard from SEGES, Published in Kvægnyt, No 13, 1 July 2016.

South Africa:

The most favourable results were obtained where a combination of treatment and vaccination was used,” and “the longer the vaccine was used, the more this advantage intensified,” – South African Dairy specialist, Dr Inge-Marie Petzer, University of Pretoria, Onderstepoort, The Dairy Mail, Vol 23, No 12, 2016 December edition.

“Immunisation (Startvac) against S. aureus can play a role, but will be noticeably better if other management interventions are introduced simultaneously,” – South African dairy farmer, Mike Black, The Dairy Mail, Vol 23, No 12, 2016 December edition.

HIPRA UNIVERSITY:

After the success of the last HIPRA UNIVERSITY held in April 2016, HIPRA Southern Africa is proud to announce that we will be hosting the third edition.

Please contact one of the HIPRA representatives below should you want to find out information about the HIPRA products or the 2017 HIPRA UNIVERSITY.

Central Area
Francois du Toit (060 974 2944)
Thomas (Tippie) Marais (072 018 8060)
Western Cape
Dr Grant van Lelyveld (060 974 2945)
Eastern Cape
Wicus Joubert (079 792 1518)
KZN
Craig Gibson (071 680 7669)
Mail: craig.gibson@mweb.co.za

NO COMMENTS

LEAVE A REPLY

17 + 7 =